Epilepsy – Landscape & Forecast – Disease Landscape & Forecast
Epilepsy, which afflicts approximately 4.7 million people in the major markets according to Clarivate epidemiology, is a heterogeneous condition requiring individualized treatment based largely on a patient’s seizure syndrome and seizure type. The market is heavily genericized, and most of the anti-epileptic drugs (AEDs) can be used as monotherapies or in combination. However, recent entrants like cenobamate, fenfluramine, and ganaxolone are carving share in the market, despite being high-priced branded products, by targeting underserved and orphan epilepsy populations. This report provides a detailed account of dynamics in this complex market, including the continued dominance of second-generation AEDs while emerging therapies nevertheless gain traction by addressing unmet needs in this diverse patient population.
Questions answered
- What is the current size of epilepsy market by country, and how do we forecast the market will evolve in the coming years?
- What key factors will shape the future market, and what drivers and barriers will influence the use of key AEDs? Will the dominance of second-generation therapies continue, and which third-generation therapies will be successful over our forecast period?
- How will high-priced third-generation AEDs fare in this highly genericized market?
- How have UCB’s Nayzilam and Neurelis’s Valtoco been integrated into the treatment algorithm?
- What are the unmet needs in the current epilepsy treatment paradigm? How will emerging therapies address these unmet needs?
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: Approximately 20 country-specific interviews with thought-leading neurologists, supported by survey data collected for this content and other Clarivate research.
Epidemiology: Diagnosed prevalence of epilepsy by country, segmented by generalized and partial-onset seizures; drug-treated cases.
Emerging therapies: Phase II: 12 drugs; Phase III / preregistration: 6 drugs.
Market forecast features: Patient-based market forecast extending through 2032, segmented by brands and generics / biosimilars.
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Epilepsy - Landscape & Forecast - Disease Landscape & Forecast
- Key Findings
- Key Updates
- Market Outlook
- Key findings
- Market drivers and constraints
- What factors are driving the market for epilepsy?
- What factors are constraining the market for epilepsy?
- Major-market sales by class in epilepsy: 2022-2032
- Major-market patient share by class in epilepsy: 2022-2032
- Total sales by region in epilepsy: 2022-2032
- Major-market sales of recently launched and emerging therapies for epilepsy: 2022-2032
- Drug-class-specific trends
- Forecast
- Etiology and Pathophysiology
- Epidemiology
- Current Treatment
- Key findings
- Treatment goals
- Key current therapies
- Overview
- Primary mechanism of action of key current drugs used for epilepsy
- Current treatments used for epilepsy
- U.S. and European approvals of key current therapies by type of seizure
- Market events impacting the use of key current therapies in epilepsy
- First-generation AEDs
- Second-generation AEDs
- Third-generation AEDs
- Outpatient rescue therapies
- Medical practice
- Unmet Need Overview
- Drug Pipeline
- Emerging Therapies
- Access & Reimbursement Overview
- Methodology
- Appendix
Ankita Sharma, M.B.A., Manager, Healthcare Research & Data Analytics, CNS/Ophthalmology Disorders. Ankita’s focus is the epilepsy market. Prior to joining the company, she was a knowledge management manager at ZS Associates. She received her M.B.A. in hospital and healthcare administration from Symbiosis International University in India.
Andrea S. Witt, Ph.D., is Director of the Central Nervous System and Ophthalmology Disorders Portfolio at Clarivate, where she oversees a team of Business Insights Analysts and Senior Directors responsible for market research encompassing Neurology, Psychiatry, Pain, and Ophthalmology.
Her interests beyond specific CNS indications included the market potential for neuroprotectants and the impact of biomarkers on CNS markets. Dr. Witt’s research, analysis, and commentaries have appeared in Barron’s, Pharmaceutical Executive, PharmaVoice, Nature Medicine, and CNBC. Dr. Witt’s previous experience includes 10 years of scientific research conducted on neurodegenerative disorders at Harvard Medical School/Brigham and Women’s Hospital, Duke University, and the University of Texas-Southwestern Medical Center, where she earned her Ph.D. degree.